Excerpts from RHB report
Analysts: Lee Cai Ling & Jarick Seet
|• Maintain BUY with unchanged DCF-derived TP of SGD0.48, 30% upside. 1H19 revenue of SGD44.6m (+9.4% YoY) was mainly contributed by the acquisition of Pheniks in Apr 2018.
We believe the positive momentum will likely sustain. The stock is trading at 14x P/E vs peers’ 20x, offering an attractive upside potential.
• Higher gross profit on steady gross margins. Gross profit increased by 10.4% and 11.3% in 2Q19 and 1H19 to SGD10.7m and SGD20.7m, due to stronger contributions from the higher-margin Diagnostic & Aesthetics segment.
Gross margin remained unchanged YoY at 46% in 1H19. We expect gross margin to be slightly compressed in 2H19 with the addition of new headcount.
• Following through its expansion plan. The group will likely add a new gynaecologist, two new paediatricians, and a radiologist in 2H19. We understand that management intends to bring on board 10-12 specialists during the current financial year to grow its key specialist verticals (obstetrics, and gynaecology & paediatrics).
With an untapped cash position of SGD9.7m from the full drawdown of its convertible loan, we believe the group is well-positioned for overseas expansion into possible new markets such as Cambodia, Thailand and Malaysia, while further strengthening its footprint in Vietnam.
• Conversion of convertible loan and proposed acquisition of additional shares in CityClinic Asia (CCAI) to capture opportunities in Vietnam. SMG has exercised its option to convert the convertible loan of USD0.69m to 177,670 ordinary shares, at the conversion price of USD3.88 apiece, and will acquire an additional 65,647 shares for USD0.26m from existing shareholders at the same price.
The group will hold an effective 24.4% in CCAI once the two transactions are completed. CCAI reported a net loss before tax of USD1.13m for FY18, and is likely to continue incurring losses in FY19F although we do not expect the losses to have a material impact on SMG. We believe it will take some time for the business to turn profitable.
|• Reiterate BUY with unchanged DCF-based TP of SGD0.48. The stock is trading at 14x P/E vs peers’ 20x. We believe the steep discount compared to its peers offers a good opportunity to buy in.
On a fundamental perspective, we believe SMG still has the potential to grow through the addition of clinics/specialists and/or stepping up its partnership with its largest shareholder, CHA Healthcare, to explore projects in the region.